| ||
| BioCryst's stock plunges after latest setback News & Observer Durham drug developer BioCryst Pharmaceuticals' stock plummeted 40 percent on Thursday after the company said late Wednesday it is suspending development of an influenza treatment that had been supported with $235 million in federal research funding ... See all stories on this topic » |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Delete this alert.
Create another alert.
Manage your alerts.
0 comments:
Post a Comment